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Available online xxxxAs the HIV/AIDS pandemic still progresses, understanding the mechanisms governing viral transmission as well
as protection from HIV acquisition is fundamental. In this context, cohorts of HIV serodiscordant heterosexual
couples (SDC) represent a unique tool. The present study was aimed to evaluate specific parameters of innate,
cellular and humoral immune responses in SDC. Specifically, plasma levels of cytokines and chemokines, HIV-
specific T-cell responses, gp120-specific IgG and IgA antibodies, andHIV-specific antibody-dependent cellular cy-
totoxicity (ADCC) activity were assessed in nine HIV-exposed seronegative individuals (ESN) and their corre-
sponding HIV seropositive partners (HIV+-P), in eighteen chronically infected HIV subjects (C), nine
chronically infected subjects known to be HIV transmitters (CT) and ten healthy HIV− donors (HD). Very low
magnitudeHIV-specific cellular responseswere found in twoout of six ESN. Interestingly, HIV+-Phad the highest
ADCCmagnitude, the lowest IgA levels and the highest IgG/IgA ratio, all compared to CT. Positive correlations be-
tween CD4+ T-cell counts and both IgG/IgA ratios and %ADCC killing uniquely distinguished HIV+-P. Additional-
ly, evidence of IgA interference with ADCC responses from HIV+-P and CT is provided. These data suggest for the
first time a potential role of ADCC and/or gp120-specific IgG/IgA balance in modulating heterosexual transmis-
sion. In sum, this study provides key information to understand the host factors that influence viral transmission,
which should be considered in both the development of prophylactic vaccines and novel immunotherapies for
HIV-1 infection.






The pandemic of HIV/AIDS is still a major public health concern
worldwide (Frank and Witten, 2016). Highly active antiretroviral ther-
apy (HAART) can diminish viral loads (VL) to undetectable levels, re-
ducing not only mortality but also transmission rates, with the
subsequent impact on a population level (Hull et al., 2014). However,iomédicas enRetrovirus y SIDA
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edicine (2017), https://doi.orgit does not cure the infection. Moreover, an effective vaccine has not
been developed yet (Deeks et al., 2016).
It is well known the fact that not all HIV-infected individuals prog-
ress to AIDS at the same rate. For instance, there is a peculiar population
of HIV+ subjects able to maintain undetectable VL for N10 years in the
absence of HAART and AIDS-related diseases. These subjects are
known as Elite Controllers (ECs). Even though the correlates of protec-
tion in these individuals have not been fully identified, it has been sug-
gested that genetic (presence of HLA-B*57, HLA-B*27, HLA-B*13 and
HLA-B*58.01) and immune (CD8+ T-cell response) host factors could
be involved (McDermott and Koup, 2012; Gonzalo-Gil et al., 2017). Sim-
ilarly, recent evidence indicated that humoral immunity could mediate
protection in this group (Lambotte et al., 2009; Ackerman et al., 2016).
In the same line, there are other individuals that, despite having
being exposed to the virus for long periods of time, are resistant to
HIV infection (Rowland-Jones andMcMichael, 1995). This phenomenonthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2 M.J. Ruiz et al. / EBioMedicine xxx (2017) xxx–xxxwas observed among (i) heterosexual partners of HIV infected people
(Ranki et al., 1989; Langlade-Demoyen et al., 1994), (ii) sex workers
(Rowland-Jones et al., 1995; Fowke et al., 1996), (iii) men who have
sex with men, (iv) intravenous drug users, (v) exposed uninfected in-
fants (Rowland-Jones et al., 1993; Cheynier et al., 1992) and, (vi)
health-care workers (Clerici et al., 1994; Pinto et al., 1995). The mecha-
nisms that allow these individuals to be “protected” from the virus are
still unknown, although several hypotheses have been proposed. To
date, only homozygosis for a 32-base pair deletion in the gene encoding
the CCR5 protein (CCR5Δ32), themajor coreceptor used by viral isolates
most frequently associated with transmission events (R5-tropic HIV-1
variants) has been consistently shown to be a determinant of HIV resis-
tance (Liu et al., 1996). Still, subjects bearing the WT ccr5 gene have
been described as resistant or less susceptible to HIV infection. Thus,
unraveling this mystery and understanding the underlying mechanism
could help in the development of novel therapies and even a vaccine.
Sexual transmission is currently the major route of HIV infection
worldwide accounting for N80% of new infections (Hladik and
McElrath, 2008). By definition, a HIV serodiscordant couple (SDC) is a
couple in which one partner is HIV-positive and the other is HIV-nega-
tive. SDC cohorts may be themost relevant groups for identifying corre-
lates of protection affecting sexual transmission. The first evidence of
resistance to infection in spite of exposure in this kind of cohorts ap-
peared in 1989, when T-cell responses to HIV proteins were observed
in the seronegative partners, later defined as exposed seronegative
(ESN) individuals (Ranki et al., 1989). Since then, cellular, humoral
and innate immune responses in ESN subjects have been studied (re-
view in (Piacentini et al., 2008)). Remarkably, there are certain aspects
of the immune response that have been recently associatedwith protec-
tion fromdisease progression but have not been investigated in the sce-
nario imposed by SDC yet. This is the case of antibody-dependent
cellular cytotoxicity (ADCC). HIV-specific ADCC-mediating antibodies
have been found in plasma of HIV-infected individuals (Forthal et al.,
2001; Dugast et al., 2014; Cereb et al., 1995), in cervicovaginal fluids
(Battle-Miller et al., 2002), breast milk (Mabuka et al., 2012) and
semen (Parsons et al., 2016) of infected subjects. Several reports suggest
that ADCC-mediating antibodies might protect infected individuals
from disease progression (Lambotte et al., 2009; Thobakgale et al.,
2012; Baum et al., 1996; Chung et al., 2011). Recently, our group dem-
onstrated that gp120-specific IgA is a plasma factor capable of modify-
ing the magnitude of IgG-mediated ADCC in HIV infection, possibly
abrogating its protective role (Ruiz et al., 2016). The presence of anti-
bodies capable of mediating ADCC at sites of viral entry raises the possi-
bility that these antibodies could modulate viral transmission, probably
by inhibiting or decreasing transmission rates. In this line, it was report-
ed that passively acquired ADCC activity in infants born to HIV-infected
mothers was not associatedwith protection but with reducedmortality
(Milligan et al., 2015).
In sum, HIV transmission is a complex phenomenon (Dale et al.,
2013). The group of SDC is a valuable set of subjects that may help us
to study not only correlates of protection in ESN, but also the existence
of possible factors involved in viral transmission. Here, we aimed to
evaluate different aspects of innate, cellular and humoral immune re-
sponses in a cohort of SDC. For this, plasma levels of 39 cytokines and
chemokines, HIV-specific T-cell responses, gp120-specific IgG and IgA
antibodies, and HIV-specific ADCC activity were evaluated in ESN from
SDC and their respective HIV+ partners (HIV+-P). Also, the same pa-
rameters were evaluated in chronically infected HIV+ subjects (C),
chronically infected subjects known to be HIV transmitters (CT) and
healthy donors (HD), for comparison purposes. We hypothesized that
the joint evaluation of the aforementioned parameters will shed light
on possible immune correlates of protection in ESN as well as possible
factors affecting viral transmission. Interestingly, ADCC magnitude,
gp120-specific IgA titers and gp120-specific IgG/IgA ratio appeared as
factors able to discriminate HIV+-P, CT and C subjects. This warrants
further studies on the role of gp120-spcific IgA, ADCC-mediatingPlease cite this article as: Ruiz, M.J., et al., Evaluation of Different Paramete
Heterosexual Couples: Humoral Re..., EBioMedicine (2017), https://doi.orantibodies and the relation of these two factors in modulating viral
transmission.
2. Materials and Methods
2.1. Study Groups
The following study groups were enrolled (Table 1): Nine
serodiscordant heterosexual couples (SDC), eighteen chronically infected
subjects (C) and nine chronically infected subjects known to be HIV trans-
mitters (CT). Also, ten healthy HIV-seronegative donors (HD) were en-
rolled as a control group. SDC were enrolled based on self-reporting
being a couple for a period longer than three years and having unprotected
sexduring that period. TheHIV+ individual of the couple (hereinafterHIV+
positive partner (HIV+-P)) self-reported being off-HAART throughout that
period and had detectable (N50HIV RNA copies/ml plasma) viral load (VL)
at themomentof enrollment. It is important tohighlight that these subjects
were not followed up by our team, and SDCwere enrolled prior to the de-
velopment of the HIV treatment guidelines which indicate that all individ-
uals with a negative partner should receive treatment as prevention.
Seronegative status of the HIV negative subject (from now on exposed se-
ronegative partner, ESN) was corroborated at the moment of enrollment.
C and CTwere defined as subjects infected for N3 years, with detect-
able VL and HAART naïve. In addition, CT had at least one transmission
event documented by self-reported, clinical and phylogenetic data
(Damilano G, unpublished). Samples from HD were obtained from
N18 year-old voluntary blood donors who completed and passed a sur-
vey on blood donation which specifically excludes persons who had
been exposed to HIV; and were screened for serological markers before
being accepted as donors.
Blood samples from HIV-infected individuals, uninfected sexual
partners from HIV-infected individuals, and healthy donors were ob-
tained for this study. Prior to enrollment, the study was reviewed and
approved by the Comité de Ética Humana, Facultad de Medicina,
Universidad de Buenos Aires. All participants provided written informed
consent accepting to participate in this study.
2.2. Samples
Plasmaandperipheral bloodmononuclear cells (PBMCs)were obtain-
ed from ESN and HIV+-P (both individuals from the SDC), HD and C. For
CT only plasma samples were obtainedwith the purpose of being used as
control group for ADCC assays. In all cases, blood samples were collected
and centrifuged to separate plasma,whichwas stored at−80 °Cuntil use.
For ADCC assays, plasma samples were first diluted (10-fold in RPMI
medium) passed through a 0.2 μm-pore filter and heat-inactivated (1 h,
56 °C). PBMCswere isolated by Ficoll-Hypaque density gradient centrifu-
gation (GE Healthcare, UK) and cryopreserved for subsequent assays.
PBMCs from one HIV negative donor were isolated, cryopreserved and
used as effector cells in ADCC assay. Cells from the same donor were
used in all assays to avoid bias from donor to donor. Plasma VL
(branched-DNA, Versant HIV-1 RNA 3.0 assay; Siemens Healthcare, UK)
and CD4+ T-cell count (flow cytometry double platform, BD FACSCanto;
BD Biosciences, USA) were assessed in all subjects.
2.3. HIV Subtype Determination
HIV-1 RNAwas extracted from 200 μl of stored plasma using the viral
RNA extraction Kit (Purelink viral RNA/DNA Mini kit, Invitrogen-Life
Technologies). Afterwards, pol gene was amplified by RT-PCR as de-
scribed before (Dilernia et al., 2013). Amplicons were purified and se-
quenced using the Big Dye Terminator sequencing kit v3.1 (Applied
Biosystems, USA) on an automated sequencer (Applied Biosystems DNA
sequencer 3500). Nucleotide sequences were analyzed andmanually ad-
justed using Sequencher v5.1 software (Gene Codes Co.). The partial pol
sequences were aligned independently of each other with HIV-1rs of Humoral and Cellular Immune Responses in HIV Serodiscordant
g/10.1016/j.ebiom.2017.11.001
Table 1
















Group SDC: serodiscordant couples (N = 9)e
HIV+-P1 F 45 6 36,364 4.56 530 02/25 8/51 BF
ESN1 M 40 b50 b1.7 1208 02/29 44CXHZ/7 −
HIV+-P2 M 47 10 95,821 4.98 41 02/08 48/35 BF
ESN2 F 43 b50 b1.7 634 01/32 44CXJC/18 −
HIV+-P3 M 37 3 21,758 4.33 370 NA NA C
ESN3 F 32 b50 b1.7 904 02/34 40CXJJ (61)/14 −
HIV+-P4 F 33 5 177 2.24 386 11/68 35/08 NA
ESN4 M 26 b50 b1.7 850 02/24 15CXHX (62)/07 −
HIV+-P5 M 34 5–7 901 2.9 160 02/02 39/39 NA
ESN5 F 73 b50 b1.7 672 01/02 8/44CXJC −
HIV+-P6 M 30 10 364,928 5.56 21 NA NA BF
ESN6 F 31 b50 b1.7 713 NA NA −
HIV+-P7 M 41 5 15,867 4.2 333 68/36 07/44CXJC BF
ESN7 F 43 b50 b1.7 606 02/11 07/38 −
HIV+-P8 M 40 N3 81 1.9 259 2/24 25/29 NA
ESN8 F 25 b50 b1.7 1214 40/35 50/36 −
HIV+-P9 F 36 N3 465 3.05 256 01/33 45/52 NA
ESN9 M 26 b50 b1.7 497 32/32 8/38 −
Group C: chronics (N = 18)
C01 F 21 − 85,947 4.9 25 11/24 35/51or78f BF
C02 M 22 − 18,580 4.2 511 1/3 7/37 B
C03 M 49 − 43,436 4.6 479 31/31 15/39
C04 M 28 − 555 2.7 555 2/3 44/51 BF
C05 M 36 − 1288 3.1 431 NA/NA NA/NA C
C06 F 27 − 1817 3.2 689 11/11 35/40
C07 M 47 − 11,026 4.0 585 2/2 44/28
C08 F 38 − 22,475 4.3 143 2/2or25f 35/55 B
C09 F 29 − 14,784 4.3 139 26/26 44/57 BF
C10 F 24 − 253,167 5.4 5 31/31 39/47 BF
C11 M 23 − 45,199 4.7 282 11/11 18/35
C12 F 50 − 3093 3.5 227 2/33 15/39
C13 F 24 − 1286 3.1 1071 2/3 35/44 BF
C14 M 26 − 22,060 4.3 293 2/2 7/35 BF
C15 M 33 − 4698 3.7 408 31/31 8/48 BF
C16 M 40 − 25,402 4,4 692 2/36 7/42 B
C17 M 73 − 58,410 4,8 575 2/2 39/52 B
C18 M 47 − 710 2,9 678 31/68 44/51 BF
Group CT: chronics with documented transmission event (N = 9)
CT01 M 39 − 25,599 4.4 223 31/X 1508 (75)/35 B
CT02 M 29 − 50,563 4.7 269 32/26 38BHS/44CXHZ F
CT03 M 38 − 383,841 5.5 8 2/68 7CXPJ/15CXHW B
CT04 F 40 − 25,899 4.4 352 2/24 15YCK/1517 BF
CT05 F 29 − 1904 3.2 357 NA/NA NA/NA BFC
CT06 M 30 − 264,322 5.4 227 11/3001 18/35 BF
CT07 M 32 − 30,020 4.4 238 NA/NA NA/NA BF
CT08 M 28 − 7666 3.8 294 NA/NA NA/NA B
CT09 M 33 − 19,250 4.2 495 NA/NA NA/NA BF
F: Female, M: Male. NA; Not available.
a Estimated time based on self-reported data on clinical questionnaire.
b Versant HIV-1 RNA 3.0 assay, Siemens. Lower and upper detection limits was 50 and 500,000 RNA copies/ml, respectively (1.7 and 5.7 log10).
c Flow cytometry double platform, FACSCanto, BD Biosciences.
d Viral subtype determined by pol gene sequencing.
e Both individuals belonging to one couple are shown in side by side lines and are indicated with the same number. HIV+-P: HIV Positive Partner, ESN: Exposed seronegative subject.
f Could not be exactly determined.
3M.J. Ruiz et al. / EBioMedicine xxx (2017) xxx–xxxreferences sequences available in Los Alamos Database (http://www.hiv.
lanl.gov/content/sequence/HIV/mainpage.html). Alignments were per-
formed with MAFFT software included in http://www.hiv.lanl.gov/
content/sequence/VIRALIGN/viralign.html (Katoh and Standley, 2014).
Subtype determination was performed separately for each sequence by
following different methods: jumping profile Hidden Markov Model
(jpHMM) (Schultz et al., 2009), recombination detection program
(RDP4) (Martin et al., 2015) and recombination analysis using cost opti-
mization (RECCO) (Maydt and Lengauer, 2006). Subtype was assigned
when at least 2 out of 3 methods used were coincident.Please cite this article as: Ruiz, M.J., et al., Evaluation of Different Paramete
Heterosexual Couples: Humoral Re..., EBioMedicine (2017), https://doi.org2.4. HLA Typing and CCR5 Characterization
Total DNAwas extracted from 2× 106 PBMCs using QIAampDNA kit
(Qiagen GmbH, Germany). HLA-A and HLA-B loci were typed, at the
two-digit level, using PCR-single-stranded oligonucleotide probes as de-
scribed previously (Cereb et al., 1995; Fernandez-Vina et al., 1997).
CCR5-Δ32 deletion was identified by differences in PCR product sizes
as in (Coloccini et al., 2014). A band of 184 bp was representative of
the normal allele while a band of 152 pb corresponded to CCR5Δ32
allele.rs of Humoral and Cellular Immune Responses in HIV Serodiscordant
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Simultaneous determination of the following 39 cytokines and
chemokines was performed using Luminex technology (MILLIPLEX
MAP Human Cytokine/Chemokine, Merck Millipore, Billerica/Massa-
chusetts, USA): EGF, Eotaxin, FGF-2, Flt-3 Ligand, Fractalkine, G-CSF,
GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1rα, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17,
IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, sCD40L, sIL-
2Rα, TGF-α, TNF-α, TNF-β, VEGF. Sampleswere processed and analyzed
as described by Giavedoni et al. (Giavedoni, 2005).
2.6. HIV-specific Cellular Immune Responses
The magnitude and specificity of the HIV-specific cellular immune
response was screened by IFN-γ ELISPOT as described previously
(Turk et al., 2008; Turk et al., 2013). Briefly, cryopreserved PBMCs
were thawed in complete RPMI medium (RPMIc; RPMI 1640 [Gibco
BRL], 10% fetal bovine serum [FBS; Gibco BRL], 2 mM L-glutamine
[Gibco BRL], 100 U/ml penicillin [Gibco BRL], 100 μg/ml streptomycin
[Gibco BRL], 10 mM HEPES [Gibco BRL]) supplemented with 50 U/ml
DNase I (Benzonase nuclease; Sigma-Aldrich) and then rested overnight
in DNase-free medium. Rested PBMCs with N95% viability were plated
on sterile 96-well plates (MultiScreen IP plates; Millipore), previously
coated with mouse anti-human IFN-γmonoclonal antibody (BD Biosci-
ences) at 105 cells/well, and peptide pools (spanning HIV proteins Nef,
Gag (three pools) and Env (five pools))were added at a final concentra-
tion of 2 μg/ml of each peptide (Potential T-cell epitope (PTE) peptide
panels corresponding to Nef, Gag, and Env proteins were obtained
from the NIH AIDS Reagent Program (Malhotra et al., 2007)). The PTE
peptides are 15 amino acids (aa) in length and contain naturally-occur-
ring 9-aa sequences that are potential T-cell determinants embedded in
the sequences of multiclade circulating HIV-1 strains worldwide. Final
DMSO concentration was always lower than 0.7%. Negative (peptide-
free medium plus 0.5% DMSO), Cytomegalovirus, Epstein Bar and Influ-
enza (CEF) peptide pool (2 μg/ml) of each peptide, NIH AIDS Reagent
Program (Currier et al., 2002), and phorbol myristate acetate (PMA)-
ionomycin (5 ng/ml PMA plus 500 ng/ml ionomycin; Sigma-Aldrich)
controls were assayed for each subject. Alternatively, 105 and 106
cells/well were tested for ESN samples. Plates were developed using bi-
otinylated anti-human IFN-γmonoclonal antibody, streptavidin-perox-
idase complex, and the 3-amino-9-ethylcarbazole (AEC) substrate
reagent set (BD Biosciences). Plates were scanned on an ImmunoSpot
reader (Cellular Technology Ltd.). Specific spot count was calculated
using the ImmunoSpot software. Results were expressed as spot-
forming units (SFU)/106 PBMCs after subtracting the negative-control
values. Gag and Env responses represented the sumof the responses ob-
tained for each of its corresponding 3 and 5 pools, respectively. Thresh-
olds for positive responseswere defined as at least 50 SFU/106 PBMCs or
asmeanSFU greater than three times themean SFUof thenegative-con-
trol wells, whichever was higher.
When stated, a modified protocol denoted as ¨expanded ELISPOT¨
was used to increase sensitivity. For this, thawed and ON rested
PBMCs were cultured in 12-well plates at a density of 2 × 106 cells/ml
in complete RPMI medium supplemented with 1800 U/ml IL-2 and in
the presence of 2 μg/ml of the corresponding HIV peptide pool, for
14 days (Goonetilleke et al., 2006; Rodriguez et al., 2009). Medium
was replaced every 72 h with freshly prepared IL-2. At day 14, ELISPOT
was performed as described above.
2.7. ELISA for Env-specific Plasma IgG and IgA
Gp120-specific IgG concentration and gp120-specific IgA titers
were determined by ELISA as described before (Ruiz et al., 2016).
96-well flat-bottomed half-area plates (GreinerBio-One, Germany)
were coated with 25 ng/well of gp120BAL. For gp120-specific IgGPlease cite this article as: Ruiz, M.J., et al., Evaluation of Different Paramete
Heterosexual Couples: Humoral Re..., EBioMedicine (2017), https://doi.orquantitation, 25 μl/well of 1/10000 (C, CT and HIV+-P) or 1/10 (ESN
and HD) plasma dilutions were dispensed in triplicate. A standard curve
was constructed, consisting in two-fold serial dilutions of the anti-
gp120 2G12 monoclonal antibody starting at 24 ng/ml. IgG detection
was performed using an anti-human IgG antibody labeledwith horserad-
ish peroxidase (HRP, Sigma-Aldrich, USA) and developed with TMB-
ELISA solution (BD Biosciences, USA). Absorption at 450 nm was read
on Multiskan EX Microplate Reader (Thermo/Labsystems). IgG concen-
tration was extrapolated from the standard curve and multiplied by the
dilution factor. Gp120-specific IgA levels were determined by end-point
titration. Two-fold serial dilutions of plasma were prepared, starting at
1:20. Secondary antibody was an anti-human IgA-HRP (Sigma-Aldrich,
USA). Plates were developed and read as described for IgG. End-point
IgA titer was defined as the reciprocal of the highest plasma dilution at
which the average OD value was ≥2-fold the average OD value of control
wells. Sera from HIV-negative subjects were tested as controls.
2.8. Rapid Fluorometric ADCC (RFADCC) Assay
The assay was performed as described by others (Gomez-Roman et
al., 2006) and later adapted by our group (Ruiz et al., 2016). Briefly,
CEM-NKR target cells (AIDS Research and Reference Reagent Program
(Howell et al., 1985)) were double-stained with PKH-26 (Sigma-Al-
drich, USA) and CFSE (Carboxyfluoresceindiacetatesuccinimidyl ester;
Molecular Probes, USA) and coated with recombinant gp120BAL (AIDS
Research and Reference Reagent Program, HIV-1BaLgp120 from
DAIDS, NIAID). After one hour, cells were dispensed in U-bottom 96-
well plates (5000 cells/well) together with different dilutions of
inactivated plasma, in triplicate. After 15 min at room temperature, ef-
fector cells (thawed and overnight rested PBMCs) were added at an ef-
fector/target ratio of 50:1. Plates were centrifuged and incubated for 4 h
at 37 °C. Cells were washed, fixed, acquired in a FACSCanto flow
cytometer (BD Biosciences, USA) and analyzed using the FACSDiva
v6.1.3 software (BD Biosciences) or FlowJO v10 (Data Analysis Software,
LLC). Target cells were initially gated in a forward scatter (FSC)-versus
side scatter (SSC) plot and subsequently gated on a SSC versus PKH-26
plot. Then, a PKH-26 versus CFSE plot was generated to determine
target-cell killing (%ADCC killing) which was calculated as the propor-
tion of cells that remained PKH-26high but had lost the viability dye
(CFSEneg). Results are presented as the media of triplicate conditions
and background-subtracted (%ADCC killing for uncoated target cells).
Threshold for positive responses for a given plasmadilutionwasdefined
as the mean of the background plus three SD.
Coating and saturation of target cells were verified by flow cytome-
trywith anti-gp120monoclonal antibody 2G12 (AIDS Research and Ref-
erence Reagent Program) followed by staining with an anti-human
IgG-APC.
2.9. Depletion of Plasma IgA
Bulk IgA was removed from plasma obtained from one representa-
tive HIV+-P and one representative CT individual using the Pierce
Immunoprecipitation kit (Thermo Scientific, USA) as described previ-
ously (Ruiz et al., 2016). Briefly, diluted and filtered plasma samples
were added to anti-IgA coupled columns, incubated overnight at 4 °C
and eluted by centrifugation. Flow-through was collected and stored
for further analysis of ADCC responses. Plasma passed through columns
coupled with an isotype-matched control antibody was used as control
(non-depleted plasma). Specific depletion of IgA was confirmed by
dot-blot and ELISA.
2.10. Data Analysis
Statistical analyses were performed using GraphPad Prism 6 Soft-
ware. Data was expressed as median values with interquartile ranges
(IQ25-75) and analyzed by non-parametric methods unless otherwisers of Humoral and Cellular Immune Responses in HIV Serodiscordant
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5M.J. Ruiz et al. / EBioMedicine xxx (2017) xxx–xxxstated. Outliers were identified by the Grubbs' method using a two-
tailed α = 0.05. Mann-Whitney test or Kruskal-Wallis plus Dunn's
post-test were used to compare variables between two or multiple
groups, respectively. Correlations were determined using Spearman's
rank test. All tests were considered significant when p value was
b0.05. When analyzing differences in soluble plasma molecules be-
tween groups, p values were adjusted for multiple comparisons using
a false discovery rate (FDR) procedure, according to the Benjamini &
Hochberg method, with R Project software version 3.3.3. Adjusted p
values were considered significant when b0.1.3. Results
3.1. Study Subject Description
Nine exposed HIV seronegative individuals (ESN) and their respec-
tive HIV+ partners (HIV+- P) were enrolled. All SDC were heterosexual.
Among them, three HIV+- P were female and six were male. Addition-
ally, eighteen chronically infected subjects (C), nine chronically infected
subjects known to be HIV transmitters (CT) and ten healthy HIV-sero-
negative donors (HD) were enrolled for this study. Details for each sub-
ject are described in Table 1. Plasma viral load (VL) and CD4+ T-cell
count were determined in all groups, except for HD. HIV+-P median
CD4+ T-cell count was 259 cell/μl and median VL was
15,867 HIV RNA copies/ml (Fig. 1). As expected, all ESN had unde-
tectable VL (according to their seronegative status at the moment
of enrollment, not shown). The ESN median CD4+ T-cell count was
713 cells/μl, which was significantly higher compared to the HIV+-
P group (p b 0.0001, Fig. 1). C and CT had a median of 455 and 269
CD4+ T-cells/μl respectively, and their median VL were 16,682 and
25,899 respectively (Fig. 1). No significant differences were found
among the C, CT and HIV+-P groups regarding VL and CD4+ T-cell
counts. It is worth noting that some HIV+-P could be considered as
“viremic controllers” due to their relative low VL (b2000 RNA cop-
ies/ml). Reduced VL has been directly associated to transmission
risk thus these subjects could be less prone to transmit the virus.
However, the fact that all HIV+-P had detectable plasma VL and
that even high VL subjects are represented within this group indi-
cates that resistance to HIV infection in enrolled ESN might be deter-
mined also by other host and/or viral factors.
Viral subtypes were determined in most of the HIV+ individuals
enrolled for this work and shown in Table 1. The frequency of each
of these viral variants within our study group was in line with the
frequency observed at the population level in our region (Dilernia
et al., 2013). In the case of ESN, the presence of protective HLA alleles
(HLA B*57, HLA-B*27, HLA-B*13 and HLA-B*58.01) was tested and
excluded (Table 1). Similarly, no ESN presented the CCR5Δ32
deletion.Fig. 1. CD4+ T-cell counts (A) and plasma viral loads (VL, B) of enrolled HIV subjects per
study group. Inclusion criteria for subjects enrolled are explained in Materials and
Methods. Horizontal lines stand for median values. HIV+-P: HIV positive partners, ESN:
Exposed HIV seronegative individuals, CT: Chronically HIV transmitters subjects C:
Chronics. P values were calculated using a Mann-Whitney U test. Asterisks denote
different p values: ***, p b 0.005,
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Plasma From ESN Compared to HD While sCD40L was Lower in HIV+-P
Compared to Chronics
In order to evaluate specific parameters of immune responses in HIV
SDC, we first assessed plasma levels of 39 cytokines and chemokines by
Luminex technology in both partners of SDCs (ESN and HIV+-P), in a
subset of twelve C and in ten HD. In all cases, ESN were compared
with HD and HIV+-P with C. Plasma levels of the macrophage-derived
chemokine (MDC) were significantly elevated in ESN, compared to HD
(median 998 and 543 pg/ml, respectively; p = 0.0220, Fig. 2A), even
at levels comparable to those of HIV-infected groups (median 1150
and 849 pg/ml for HIV+-P and C, respectively, p ≥ 0.05). No other signif-
icant differences were obtained when comparing ESN with HD. On the
other hand, sCD40L, an inflammation biomarker associated with AIDS
progression (Sipsas et al., 2002), was detected in significantly lower
levels in HIV+-P compared to C (median 647 and 2241 respectively; p
= 0.0097, Fig. 2B). Even when removing one outlier identified in the
dataset corresponding to C, the difference with the HIV+-P remained
statistically significant (p= 0.0172). Moreover, sCD40L levels obtained
for HIV+-P were not different from the levels observed in ESN and HD
(median 563 and 640 pg/ml, respectively). However, these differences
were lost when applying the FDR procedure.
Thus, no major difference was observed among soluble cytokines
and chemokines when comparing plasma obtained from HD and ESN
or HIV+-P and C. Out of the 39 cytokines evaluated, only MDC and
sCD40L were significantly different in ESN (compared to HD) and
HIV+-P (compared to C) respectively. Even when MDC was described
to have HIV suppressive activity (Pal et al., 1997) and sCD40L was re-
ported to be elevated in progressive HIV-1 infection, our data set lacks
power to identify these molecules as potential factors involved in mod-
ulating HIV transmission events.3.3. Only a Minor Proportion of ESN Showed HIV-specific Cellular Response
and it was of Very Low Magnitude
Next, HIV-specific T-cell responses directed towards Nef, Gag and
Env proteins were evaluated by ELISPOT in six out of nine SDC. A con-
ventional eighteen-hour stimulation ELISPOT protocol was first used.
No significant differences were observed between HIV+-P and C either
in magnitude (Fig. 3A, left panel) or immunodominance (Fig. 3A, right
panel) of the cellular HIV-specific response. The HIV+-P group showed
a slightly higher magnitude for all antigens, even for the CEF control
peptide pool. Also, it was observed that the response was broader
than in C, which showed a Gag-concentrated response. However,Fig. 2. Differential plasma cytokine/chemokine levels among groups. A. Macrophage-
derived chemokine (MDC) levels (pg/ml) in plasma from exposed HIV seronegative
individuals (ESN) versus healthy donors (HD). B. sCD40L levels (pg/ml) in plasma from
HIV positive partners (HIV+-P) versus Chronics (C). P values were calculated using a
Mann-Whitney U test. Asterisks denote different p values: *, p b 0.05, **, p b 0.001. After
applying the FDR procedure, adjusted p value was N0.1.
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Fig. 3. ELISPOT screening of HIV-specific T-cell response magnitude and breadth in HIV+-P, ESN and Chronics. A. Magnitude (SFU/106 PBMC, left panel) and breadth (contribution of each
antigen relative to the total HIV response, right panel) of the HIV-specific T-cell responses in HIV+-P and Chronics. In the case of the magnitude, results corresponding to the CEF control
peptide pool (Cytomegalovirus, Epstein Bar, Influenza) are also shown. Horizontal lineswithin boxes represent themedian values.Whiskers extend frommin tomax values. B.Magnitude
(SFU/106 PBMC) of the HIV-specific and CEF-specific responses in three ESN individuals, obtained in the “fresh” (conventional) and “expanded” (14-day stimulation) ELISPOT protocol.
Bars represent the media ± SD from triplicate conditions.
6 M.J. Ruiz et al. / EBioMedicine xxx (2017) xxx–xxxthese observations were all trends and no statistically significant differ-
ences were found.
In the conventional ELISPOT protocol, three ESN (ESN3, ESN5 and
ESN7) showed detectable responses but below the assay cut-off (15,
47 and 40 SFU/106 PBMCs, Fig. 3B). We reasoned that this could be spe-
cific responses but of very low magnitude. To address this possibility, a
14-day stimulation protocol (expanded protocol) was applied. Expand-
ed cells from ESN5 and ESN7 showed a significant 4- and 6-fold in-
crease, respectively, in the HIV-specific response (Fig. 3B). Conversely,
no response was observed in ESN3 after the expansion with the corre-
sponding HIV peptide pool. However, expansion with the CEF peptide
pool in this subject resulted in a 95-fold increase in the magnitude of
the CEF-specific response, compared to the fresh protocol, which indi-
cated that the cells were viable and responsive to CEF but not to HIV
peptides. Additionally, the 14-day stimulation protocol was tested in a
subset of five HDs against all HIV peptide pools and the control CEF
pool. No positive HIV-specific responses were found, further confirming
the specificity of this protocol (not shown).
Overall, no significant difference was observed in the HIV-specific
cellular immune response between HIV+-P and C. Out of the 6 ESN test-
ed, only two had HIV-specific cellular immune responses whichwere of
very low magnitude, confirmed by an expanded ELISPOT protocol. This
could be an indication of continuous exposure to the virus.
3.4. Most HIV+- P had Higher ADCC Responses Compared to Chronics and
CT and Also Statistically Higher gp120-specific IgG/IgA Ratios
Then, we sought to evaluate immune parameters related with hu-
moral immunity that may be implicated in resistance to HIV infection
and/or related with lower transmission rates. More specifically, wePlease cite this article as: Ruiz, M.J., et al., Evaluation of Different Paramete
Heterosexual Couples: Humoral Re..., EBioMedicine (2017), https://doi.oraimed to determine if ADCC responses could be a novel factor involved
in resistance to HIV infection. Thus, ADCC responses were initially eval-
uated in all HIV+-P and ESN, and in a subset of 13C and 6HD. Zebra plots
from one representative subject from each group are shown in Fig. 4A.
ESN had undetectable ADCC responses, similarly to that observed in
HD, excludingADCC as amechanism involved in protection (Fig. 4B). In-
terestingly, HIV+-P showed significantly higher percentages of ADCC
killing (median 48.03%) compared to C (median 12.93%, p ≤ 0.0001).
This result raised the hypothesis that ADCCmight be involved in lower-
ing transmission rates. However, the group of chronic subjects is a het-
erogeneous group that includes individuals who may potentially have
transmitted the infection to others, aswell as individualswho potential-
lymayhave not. So, a group of chronically infected subjects known to be
HIV transmitters (CT)was specifically enrolled. By doing this, we aimed
to compare levels of ADCC responses between HIV non-transmitters
(HIV+-P) and documented HIV transmitters (CT). Unfortunately, limit-
ed samplewas obtained from this group and only ADCC and gp120-spe-
cific antibodies could be measured in this group (no ELISPOT or plasma
soluble factors). Notably, HIV+-P still showed significantly higher levels
of ADCC responses (median 48.03%) compared to CT (median 43%, p=
0.039, Fig. 4B). Also, CT had significantly higher levels of ADCC com-
pared to C (median 43% vs.12.93% respectively, p = 0.0040). When re-
moving the outlier identified within the CT dataset, the p value
between HIV+-P and CT raised to 0.07. Still, most (6 out of 9) HIV+-P
had ADCC values above the IQ75% of CT. Thus, even when significance
was lost after outlier removal, probably driven by the small sample
size, the finding still deserves attention. Afterwards, we decided to in-
vestigate if gp120-specific IgG and IgA levels and IgG/IgA ratios may in-
fluence the ADCC responses observed in this study, as reported
previously by our group in subjects undergoing primary HIV infectionrs of Humoral and Cellular Immune Responses in HIV Serodiscordant
g/10.1016/j.ebiom.2017.11.001
Fig. 4. A. ADCC responses in Serodiscordant Couples (HIV+-P and ESN), HIV chronically infected individuals (C) and HIV chronically infected transmitter subjects (CT), measured by
RFADCC assay. Zebra plots for one representative subject per study group. A PKH26-versus-CFSE plot was generated to determine the percentage of ADCC killing, defined as the
proportion of cells that remained PKH26high but lost the viability dye (CFSEneg). Percentages shown in each plot correspond to results obtained after calculating and subtracting the
background (%ADCC killing for uncoated target cells) from the media of triplicate conditions. B. Percentages of ADCC killing corresponding to a 1/1000 plasma dilution for HIV+-P, C
and CT, and to a 1/100 plasma dilution for HD and ESN. %ADCC killing data correspond to background subtracted values. Horizontal lines stand for median values. Statistical analysis
was performed using Kruskal-Wallis test followed by Dunn's multiple comparisons post-test. # When the outlier identified within the CT group was removed, the statistical
significance was lost (p = 0.07). C. Gp120-specific IgG antibodies (log10(nanograms per milliliter), left panel), gp120-specifc IgA titers (middle panel) and IgG/IgA ratios (right panel)
per study group. Horizontal lines stand for median values. Statistical analysis was performed using Kruskal-Wallis test followed by Dunn's multiple comparisons post-test. HIV+-P: HIV
positive partners, ESN: Exposed HIV seronegative individuals, CT: Chronically HIV transmitters subjects C: Chronics. HD: Healthy donors.
7M.J. Ruiz et al. / EBioMedicine xxx (2017) xxx–xxxand ECs (Ruiz et al., 2016). For that purpose, gp120-specific IgG and IgA
levels were determined. ESN had undetectable levels of both gp120-
specific IgG and IgA antibodies, as inHD(Fig. 4C, left andmiddle panels).
As expected, HIV+-P, C and CT individuals had detectable gp120-specif-
ic IgG concentrations, but no differences were observed among these
groups (Fig. 4C, left panel). This was particularly interesting since
HIV+-P showed higher ADCC responses both compared to C and CT,
with comparable levels of anti-gp120 IgG antibodies. On the other
hand, CT had significantly higher IgA titers compared to HIV+-P (p =
0.0185) and C (p= 0.0001) (Fig. 4C, middle panel). Finally, IgG/IgA ra-
tioswere calculated for theHIV-infected groups (HIV+-P, C and CT).We
studied this ratio because the balance between gp120-specific IgG and
IgA had been implicated in shaping ADCC responses (Tomaras et al.,
2013) (Ranki et al., 1989; Cereb et al., 1995). The highest IgG/IgA ratioPlease cite this article as: Ruiz, M.J., et al., Evaluation of Different Paramete
Heterosexual Couples: Humoral Re..., EBioMedicine (2017), https://doi.orgwas observed in HIV+-P and the lowest in CT, with a statistically signif-
icant difference between them (Fig. 4C, right panel; p= 0.0040), while
Cs showed an intermediate situation.
3.5. Positive Correlations Between CD4+ T-cell Counts and Both IgG/IgA Ra-
tios and %ADCC Killing Distinguish HIV+-P
So far, we have identified that most HIV+-P present the highest
ADCC responses and that this group showed the highest IgG/IgA ratio,
compared to CTs and C. Inversely, CTs showed the highest gp120-
spefific IgA titers. In a previous report from our group, we showed
that both themagnitude of ADCC responses and its associationwith dis-
ease progression were influenced by gp120-specific IgA levels (Ruiz et
al., 2016). To provide a better insight into the relation of these factorsrs of Humoral and Cellular Immune Responses in HIV Serodiscordant
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bodieswere studied in these groups. In linewith results reported previ-
ously by our group in other cohorts (Ruiz et al., 2016), gp120-specific
IgG and %ADCC killing correlated positively in CT (r = 0,7857, p =
0.0279) and HIV+-P, although the correlation was not statistically sig-
nificant in the latter group (r = 0.5333, p = 0.1475). On the contrary,
no correlation was observed between gp120-specific IgA and %ADCC
killing in either group (not shown). A strong positive correlation was
found between IgG/IgA ratios and %ADCC killing in HIV+-P (r =
0.8500; p = 0.0061), suggesting that the balance between gp120-spe-
cific IgG and IgA might modulate the magnitude of ADCC responses in
this group. On the other hand, this correlation was less clear in CT andFig. 5. A. Correlations between %ADCC Killing versus IgG/IgA ratios, IgG/IgA ratios versus CD4+
(right panels) individuals. r and p valueswere determined by Spearman's test. ns: non-significa
of the ADCCoutlier data point identifiedwithin the CT group. B. Percentage of ADCCkilling evalu
Plasma was obtained from representative HIV+-P and CT individuals. ADCC was evaluated in t
Please cite this article as: Ruiz, M.J., et al., Evaluation of Different Paramete
Heterosexual Couples: Humoral Re..., EBioMedicine (2017), https://doi.oronly resulted statistically significant when removing the ADCC outlier
data point identified within this group (Fig. 5A, upper panels). Interest-
ingly, another unique feature of HIV+-Pwas a significant correlation be-
tween IgG/IgA ratios and CD4+ T-cell counts which was neither
observed in CT (Fig. 5A, middle panels) nor in Chronics (r = −0.1364,
p = 0,6937, not shown).
Then, we sought to investigate if ADCC responses in HIV+-P and CTs
could be related to markers of disease progression such as CD4+ T-cell
count or VL. For that purpose, correlation analyses between clinical pa-
rameters and %ADCC killing observed in HIV+-P, C and CT were per-
formed. As expected, no correlations were observed between ADCC
values and VLs in either group (not shown) or CD4+ T-cell counts inT-cell counts and CD4+ T-cell counts versus %ADCC killing in HIV+-P (left panels) and CT
nt. r and p values shown between brackets correspond to those obtained after the removal
ated in IgA-depleted (grey bars) and non-depleted (black bars) plasma at 1/1000 dilutions.
riplicates and data was analyzed by t-test.
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9M.J. Ruiz et al. / EBioMedicine xxx (2017) xxx–xxxCs (r=−0.0109, p=0.9758 not shown) or CTs (Fig. 5A, lower panels).
The lack of correlation between these parameters remained whether
the outlier was included in the analysis or not. On the contrary, a signif-
icant positive correlation between %ADCC killing and CD4+ T-cell
counts were observed in HIV+-P (r = 0.7833, p = 0.0172), as shown
in Fig. 5A (lower panel). In contrast to our previous evidence indicating
that, in viremic subjects, a protective role of ADCC antibodies was only
evidenced when there were low IgA plasma levels (Ruiz et al., 2016),
the scenario resulted different in HIV+-P. In this group, in spite of
being viremic, ADCC response seems to play a protective role (in
terms of CD4+ T-cell counts) which could also be related to lower
viral transmission rates. Alternatively, it provides further evidence of
the mitigating role of IgA in ADCC magnitude since this correlation in
only observed in the group with the highest IgG/IgA ratio.
Based on these results, we went one step further to investigate if
gp120-specific IgA from HIV+-P and CT were able to mitigate ADCC re-
sponses, as reported by our group in other cohorts (Ruiz et al., 2016).
For this, plasma IgA was depleted from one representative HIV+-P and
one representative CT individual. Then, ADCC was reevaluated in IgA-
depleted and non-depleted plasma. As shown in fig. 5B, ADCCwasmod-
ulated after IgA removal in both cases, although the extent of the mod-
ulation varied. The %ADCC killing of IgA-depleted plasma from the
HIV+-P was around 13% higher compared to the undepleted plasma.
However, this difference reached 33% in the CT, indicating that the IgA
from the CT mitigated the ADCC responses to a greater extent than the
IgA from the HIV+-P. Although these results come from only two indi-
viduals and cannot be extended to the whole groups, they provide the
first evidence of IgA interference with ADCC responses in HIV+-P and
CT.
Overall, these results allow us to state that, even though ADCC anti-
bodies were associated with protection from infection in different set-
tings (Mabuka et al., 2012; Rerks-Ngarm et al., 2009), they were not
detectable in ESN. Conversely, the fact thatmost HIV+-P had higher per-
centages of ADCC killing when compared to CT made us hypothesize
about an association between ADCC and a lower rate of viral transmis-
sion. This could be directly related to ADCC activity or with the balance
between gp120-specific IgG and IgA antibodies. In fact, the opposite sce-
narios imposed by CT andHIV+-Pwere characterized by the highest IgA
titers and the highest IgG/IgA ratios, respectively. This suggests that IgA
might have a negative impact on HIV transmission. Then, ADCC levels in
HIV+-P were directly associated with IgG/IgA ratios and CD4+ T-cell
counts, feature uniquely found in this group. Finally, evidence of IgA-
mediatedmitigation of ADCC responses in HIV+-P and CTwas provided.
This point certainly deserves further consideration.
4. Discussion
Understanding the mechanisms underlying protection against HIV
acquisition and/or disease progression will be instrumental to enhance
current therapeutic regimens, as well as to develop strategies to cure
HIV and to design successful vaccine candidates. In this context, the
study of serodiscordant couples (SDC) gives a unique scenario to evalu-
ate both correlates of protection in exposed HIV seronegative individ-
uals (ESN) and also the existence of intrinsic factors in the HIV+-P
that may be involved in modulating viral transmission. Among these
factors, VL is a major determinant of transmission risk, i.e. reduced VL
(as those found in viremic controllers) was associated with reduced
transmission risk (Hull et al., 2014; Blaser et al., 2014). Within our
group of HIV+-P, four out of nine subjects fell within this category
thus their “viremic controller” status might be determining the lack of
transmission to their partners. However, the fact that they had detect-
able VL and also the observation of subjects with high VLs within the
HIV+-P group made us hypothesize about other factors influencing
the success of the transmission event. Thus, here we assessed different
aspects of the humoral and cellular HIV-specific immune responses in
nine ESN and their respective HIV+-P. We covered the evaluation ofPlease cite this article as: Ruiz, M.J., et al., Evaluation of Different Paramete
Heterosexual Couples: Humoral Re..., EBioMedicine (2017), https://doi.org(i) plasma levels of 39 cytokines and chemokines, (ii) HIV-specific
T-cell responses in PBMCs, (iii) plasma gp120-specific IgG and IgA
antibodies, and (iv) plasma ADCC activity. This study about different
immune parameters was undertaken based on the hypothesis that
resistance to HIV infection may rely on multiple host's features and
also that different and combined, host, viral and environmental
causes may compromise or enhance the success among transmission
opportunities. Indeed, we found evidence of signatures possibly in-
volved in diminishing transmission in HIV+-P (higher ADCC magni-
tude, higher IgG/IgA ratio, protective ADCC responses) versus
favoring transmission efficacy in CT (higher gp120-specific IgA
titers).
First, we showed that macrophage-derived chemokine (MDC) was
slightly elevated in plasma from ESN, compared to HD. On the other
hand, the highest plasma levels of sCD40 were found in C. Although
the differences lost statistical significance after correction for multiple
comparisons, a few issues are worth discussing. In previous reports,
higher MDC level was associated with a better outcome in children on
HAART (Lambert et al., 2007) and was directly correlated with Th17
cell counts in HIV-infected subjects (Falivene et al., 2015). Moreover, it
had anti-HIV activity in in vitro experiments (Pal et al., 1997). This find-
ing adds evidence to those reports regarding the role of innate immuni-
ty in protecting ESNs. Specifically, it has been previously reported that
expression levels of the antiviral factors APOBEC3G (Biasin et al.,
2007) and Mx2 (Stein et al., 2015), Vitamin D receptor
(Aguilar-Jimenez et al., 2013; Aguilar-Jimenez et al., 2016), β-defensins
(Zapata et al., 2008), IL-22 and acute-phase amyloid A protein (Misse et
al., 2007) aswell as increased responsiveness to TLR stimulation (Biasin
et al., 2010) and increased NK cell activity (Ravet et al., 2007; Montoya
et al., 2006; Scott-Algara et al., 2003) were associated with protection
from infection in this group. Regarding sCD40L, our finding is consistent
with a previous report by Sipsas et al. (2002) that showed elevated con-
centrations of circulating sCD40L in individuals infected with HIV-1
compared to healthy controls. Despite being infected and contrary to
C, HIV+-P had sCD40L levels comparable to HD. Others have reported
that sCD40Lmay impair dendritic cell functionality duringHIV infection
(Miller et al., 2015). Thus, our result would indicate that HIV+-P would
be protected from this phenomenon.
Nevertheless, it is clear that the subtle differences in MDC between
ESN and HD and in sCD40L between HIV+-P and C do not explain the
difference behavior of each group. Thus, whether this has a direct role
in HIV transmission or, more likely, other factors are also involved war-
rants further research. In this line, humoral and cellular HIV-specific im-
mune responses were investigated in this study. As expected, HIV-
specific cellular immune responses were broadly and readily detected
by fresh ELISPOT in C and HIV+-P, and no significant differences were
found between these groups. Unfortunately, ELISPOT responses could
not be measured in CT due to the unavailability of PBMC samples, be-
cause this group was enrolled a posteriori and specifically for ADCC
and antibodies determination. Conversely, positive responses in ESNs
were infrequent (in 2 out of 6 subjects) and of very low magnitude.
This result is in line with several reports indicating that detection of
HIV-specific cellular immune responses in PBMCs from ESN can only
be evidenced after cultured, expanded or boosted protocols and, still,
subjects with positive responses are the less abundant (Ruiz-Riol et al.,
2015; Guardo et al., 2015; Ritchie et al., 2011; Addo et al., 2011;
Guthrie et al., 2012; Pala et al., 2013; Nguyen et al., 2006; Alimonti et
al., 2006). Then, the interpretation of those positive responses should
be done with caution. The most accepted hypothesis claims that it
should be considered as indicators of repetitive exposure to the virus.
Alternatively, these responses could be considered preformed correlates
of protection against HIV infection. Out of the 2 ESN with positive
ELISPOT responses in this study, one had a partner with high viral load
(15,867 copies/ml) while the other one had a partner with low viral
load (901 copies/ml). Thus, neither hypothesis can be excluded. This
highlights that further prospective studies are needed.rs of Humoral and Cellular Immune Responses in HIV Serodiscordant
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10 M.J. Ruiz et al. / EBioMedicine xxx (2017) xxx–xxxRegarding humoral responses, systemic gp120-specific IgG or IgA
antibodieswere not detected in ESN suggesting that humoral immunity
would not be involved in resistance to HIV infection. However, this hy-
pothesis cannot be discarded since the presence of antibodies with
specificities other than gp120 (for instance Gp41) aswell as HIV-specif-
ic antibodies at mucosa sites should be considered. Unfortunately, we
were unable to perform such evaluations for this work. In this line,
one recent report indicated that ESNs may show plasma IgG or IgA
that recognize cryptic Env native epitopes that cannot be detected by
regular ELISA diagnostic assays (Carrillo et al., 2013). In our perspective,
it is unlikely that ESN enrolled in this study had this kind of antibodies,
since theywould have been detected in ADCC assays (discussed below).
Also, it has been demonstrated that HIV-exposed individuals that are
persistently seronegative can present HIV-specific IgAs in urine and
vaginal wash samples (Mazzoli et al., 1997) and also develop mucosal
HIV-specific IgAs capable of blocking viral transcytosis (Lo Caputo et
al., 2003). Unfortunately, we were not able to obtain this kind of sam-
ples for our study.
Finally, it has been recently shown that HIV-specific ADCC responses
may generate protection fromHIV infection in the context of vaccine tri-
als (Rerks-Ngarm et al., 2009), as well as protection from disease pro-
gression in different cohorts of HIV infected subjects undergoing acute
(Forthal et al., 2001; Dugast et al., 2014) and chronic infection
(Lambotte et al., 2009; Thobakgale et al., 2012; Chung et al., 2011).
However, there are no reports in the literature that evaluate ADCC re-
sponses in SDC. ESNs had undetectable plasmaADCC responses, similar-
ly to that observed in HD excluding ADCC as a mechanism involved in
protection. However, ADCC in other body fluids relevant to HIV trans-
mission have not been tested so this cannot be categorically confirmed.
On the other hand, HIV+-P had the highest percentages of ADCC killing.
It was significantly higher than that of Cs and higher than that of most
CTs. Several reports, including a report from our group, demonstrated
that ECs and even VCs show enhanced ADCC function (Lambotte et al.,
2009; Ackerman et al., 2016; Ruiz et al., 2016; Madhavi et al., 2017;
Johansson et al., 2011). Thus, the highest ADCC observed in HIV+-P
group could be influenced by the inclusion of VCs within this group.
To exclude this possibility, ADCC was compared between VC HIV+-P
versus non-VC HIV+-P and no significant difference was found (data
not shown,p=0,68). This reinforced thehypothesis about the potential
role of ADCCmodulatingHIV transmission. This result is particularly rel-
evant given that similar findings have been reported in other settings
but never in a scenario involving sexual transmission. For instance,
Mabuka and colleagues (Mabuka et al., 2012) demonstrated that moth-
er-to-child transmission decreases due to the presence of antibodies ca-
pable of mediating ADCC present in breast milk, associating these
antibodies with lower transmission rates. Another recent study provid-
ed evidence indicating that pre-existing levels of IgG1 type antibodies in
infants born to HIV+ mothers correlated with increased ADCC re-
sponses and lower mortality upon infection (Milligan et al., 2015). Re-
cently, Parsons et al. (Parsons et al., 2016) reported that seminal
plasma from HIV infected individuals on HAART contained antibodies
capable ofmediating ADCC. Thesefindings add to existing data account-
ing for the presence of antibodies capable of mediating ADCC in vaginal
and cervical fluids (Battle-Miller et al., 2002; Nag et al., 2004). Taken to-
gether, these evidences provide rational criteria for investigating the
presence of ADCC-mediating antibodies in mucosa tissue and body
fluids from HIV+ individuals engaged in SDCs and their potential role
on HIV transmission. It is worth noting here that, even when the most
relevant result found in this study is the fact that HIV+-P showed signif-
icantly higher ADCC than C, and that most HIV+-P showed higher ADCC
than CT, the observation that both HIV+-P and CT revealed significantly
higher percentages of ADCCkilling compared to C cannot be overlooked.
The magnitude of ADCC response found in C was similar to that ob-
served in a previous study from our group for a similar cohort of chron-
ically infected subjects (Ruiz et al., 2016), confirming this result.
Alternatively, these results may suggest that ADCC and IgA might havePlease cite this article as: Ruiz, M.J., et al., Evaluation of Different Paramete
Heterosexual Couples: Humoral Re..., EBioMedicine (2017), https://doi.ora differential impact on HIV transmission. In this line, higher ADCC
levels observed in HIV+-P were associated with higher IgG/IgA ratios
or, in other words, a more favourable balance between the levels of
gp120-specific IgG and IgA. On the other hand, CTs showed the lowest
IgG/IgA ratios and the highest levels of gp120-specific IgA. Thus, high
ADCC responses but in a context of elevated IgA might be predisposing
to transmission. Moreover, it was found that gp120-specific IgA com-
promised ADCC responses in both HIV+-P and CTwith different intensi-
ties, although this remains to be confirmed in subsequent studies. This
finding adds evidence to previous results fromour group demonstrating
that gp120-specific IgA was capable of modifying ADCC responses, not
only in the vaccine setting as demonstrated by Tomaras et al.
(Tomaras et al., 2013) but also during progressive natural HIV infection
(Ruiz et al., 2016).
New to this study is the fact that significant correlations between
CD4+ T-cell count versus IgG/IgA ratios and versus %ADCC killing
were only found inHIV+-P allowing us to identify signatures that define
non-transmitter HIV+ individuals. The fact that these positive correla-
tions were only seen in individuals with the highest IgG/IgA ratios
(HIV+-P) is in consonancewith our previous observations found in vire-
mic subjects, where a protective role of ADCC antibodies is only evi-
denced after plasma IgA removal (Ruiz et al., 2016). Besides providing
further support to this notion, these results allow to postulate that
these factors (ADCC and IgG/IgA balance) could be related to lower
viral transmission rates. It remains to be determined whether antibody
specificities, avidity, Ig subclasses or any other factors are involved in
this effect. It is also of interest to uncover the reasons underlying the dif-
ferential magnitude of gp120-specific IgA between HIV+-P and CTs.
One point that raises concern when analyzing HIV-specific immune
responses is viral variability. Responses can be severely underestimated
if not choosing the proper reagents. Particularly in Argentina, B and BF
subtypes are themost prevalent, followed by aminor proportion of sub-
type C infections (Dilernia et al., 2013). The frequency of viral variants
found in this work matches those observed at a population level
(Table 1). In this scenario, cellular responses were evaluated using the
multiclade PTE peptide panels. Our group have previously used these
panels in samples obtained from BF infected subjects from Argentina
(Turk et al., 2013; Ghiglione et al., 2014; Rodriguez et al., 2012) proving
its efficiency. Regarding humoral responses, the gp120 protein used in
the ADCC and in the ELISA assays to detect gp120-specific IgG and IgA
was a recombinant gp120 derived from a subtype B strain. Hypotheti-
cally, this could lead to an underestimation of the response in non-B in-
fected subjects. Unfortunately, no recombinant gp120 protein from
CRF12_BF strains or other BF recombinant forms are available so as to
use the protein corresponding to the autologous subtype in the assays.
To overcome this issue, we compared %ADCC killing and HIV-specific
IgG and IgA levels between B and BF infected subjects from our study
groups. No differenceswere observedwhen segregating the subjects ac-
cording to the viral subtype, across all study groups (data not shown).
Thus, at least in this study, results are not being influenced at this level.
Broadly neutralizing antibodies are able to inhibit HIV cell-to-cell
transmission as described by Malbec et al. (Malbec et al., 2013). But if
this is also the case of ADCC antibodies, still needs to be proved. There-
fore, it would be particularly interesting to examine whether ADCC
serum and mucosal antibodies may also contribute to avoid HIV-1
cell-to-cell spread in vitro, and the way this mechanism is modulated
by IgG and IgA levels.
To the best of our knowledge, this is the first report evaluating mul-
tiple factors potentially involved in HIV transmission and in protection
from acquiring the infection in a SDC cohort from Argentina. More im-
portantly, this is the first report that evaluates ADCC responses in the
context of HIV SDC and in comparisonwith C and CT.We found possible
factors involved in modulating transmission rates. Particularly, it
was shown that HIV+-P had higher ADCC levels, most likely driven
by a beneficial IgG/IgA balance. However, CTs showed the highest
gp120-specific IgA levels. Correlation analyses showed that ADCCrs of Humoral and Cellular Immune Responses in HIV Serodiscordant
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11M.J. Ruiz et al. / EBioMedicine xxx (2017) xxx–xxxresponses and IgG/IgA balance were directly associated with CD4+
T-cell counts uniquely in HIV+-P. Also, initial evidence is provided
regarding a mitigating role of gp120-specific IgA on ADCC responses
in HIV+-P and CT. These data provide key aspects to understand the
host factors involved in this phenomenon and allow the visualization
of further investigations. Moreover, it also provides support for
mechanisms that should be considered both in the development of
prophylactic vaccines as well as novel immunotherapies against
HIV infection.
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